纳米医学:现状与未来展望。

Nanomedicine: current status and future prospects.

作者信息

Moghimi S Moein, Hunter A Christy, Murray J Clifford

机构信息

Molecular Targeting and Polymer Toxicology Group, School of Pharmacy, University of Brighton, Brighton, UK.

出版信息

FASEB J. 2005 Mar;19(3):311-30. doi: 10.1096/fj.04-2747rev.

Abstract

Applications of nanotechnology for treatment, diagnosis, monitoring, and control of biological systems has recently been referred to as "nanomedicine" by the National Institutes of Health. Research into the rational delivery and targeting of pharmaceutical, therapeutic, and diagnostic agents is at the forefront of projects in nanomedicine. These involve the identification of precise targets (cells and receptors) related to specific clinical conditions and choice of the appropriate nanocarriers to achieve the required responses while minimizing the side effects. Mononuclear phagocytes, dendritic cells, endothelial cells, and cancers (tumor cells, as well as tumor neovasculature) are key targets. Today, nanotechnology and nanoscience approaches to particle design and formulation are beginning to expand the market for many drugs and are forming the basis for a highly profitable niche within the industry, but some predicted benefits are hyped. This article will highlight rational approaches in design and surface engineering of nanoscale vehicles and entities for site-specific drug delivery and medical imaging after parenteral administration. Potential pitfalls or side effects associated with nanoparticles are also discussed.

摘要

美国国立卫生研究院最近将纳米技术在生物系统治疗、诊断、监测和控制方面的应用称为“纳米医学”。对药物、治疗和诊断剂的合理递送与靶向研究处于纳米医学项目的前沿。这些研究涉及确定与特定临床病症相关的精确靶点(细胞和受体),并选择合适的纳米载体以实现所需反应,同时将副作用降至最低。单核吞噬细胞、树突状细胞、内皮细胞和癌症(肿瘤细胞以及肿瘤新生血管)是关键靶点。如今,纳米技术和纳米科学在颗粒设计与配方方面的方法正开始扩大许多药物的市场,并为该行业内一个高利润细分领域奠定基础,但一些预期的益处被夸大了。本文将重点介绍纳米级载体和实体在设计及表面工程方面的合理方法,用于非肠道给药后的定点药物递送和医学成像。还将讨论与纳米颗粒相关的潜在陷阱或副作用。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索